Add like
Add dislike
Add to saved papers

Efficacy of Standardized Process Management of Early Postoperative Enteral Nutrition After Laparoscopic Hepatectomy: A Randomized Controlled Trial.

BACKGROUND: We sought to investigate the efficacy of standardized process management of early postoperative enteral nutrition in patients undergoing laparoscopic hepatectomy.

METHODS: From January 2022 to January 2023, a total of 98 patients undergoing laparoscopic hepatectomy in our hospital were enrolled in this prospective study. The participants were allocated into the study group (49 cases, given standardized process management of early postoperative enteral nutrition) and the control group (49 cases, given conventional early postoperative enteral nutrition) based on a random number table. Observation indicators included postoperative recovery, nutritional status, quality of life, and complications.

RESULTS: The time of first anal exhaust, eating, off-bed, first defecation, and postoperative hospital stay in the 2 groups was significantly shorter than those in the control group (P<0.05). After the intervention, the levels of transferrin, prealbumin, and albumin in the study group were evidently higher than those in the control group (P<0.05). The scores of overall health, body pain, body function, physiological function, vitality, social function, emotional function, and mental health in the study group were significantly higher than those in the control group after intervention (P<0.05).

CONCLUSIONS: The standardized process management of early postoperative enteral nutrition showed promising results in effectively improving the nutritional status, rehabilitation, and quality of life, as well as reducing the incidence of related complications among patients undergoing laparoscopic hepatectomy, which supports a wide application in clinical practice.

Full text links

We have located links that may give you full text access.
Can't access the paper?
Try logging in through your university/institutional subscription. For a smoother one-click institutional access experience, please use our mobile app.

For the best experience, use the Read mobile app

Group 7SearchHeart failure treatmentPapersTopicsCollectionsEffects of Sodium-Glucose Cotransporter 2 Inhibitors for the Treatment of Patients With Heart Failure Importance: Only 1 class of glucose-lowering agents-sodium-glucose cotransporter 2 (SGLT2) inhibitors-has been reported to decrease the risk of cardiovascular events primarily by reducingSeptember 1, 2017: JAMA CardiologyAssociations of albuminuria in patients with chronic heart failure: findings in the ALiskiren Observation of heart Failure Treatment study.CONCLUSIONS: Increased UACR is common in patients with heart failure, including non-diabetics. Urinary albumin creatininineJul, 2011: European Journal of Heart FailureRandomized Controlled TrialEffects of Liraglutide on Clinical Stability Among Patients With Advanced Heart Failure and Reduced Ejection Fraction: A Randomized Clinical Trial.Review

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app

Read by QxMD is copyright © 2021 QxMD Software Inc. All rights reserved. By using this service, you agree to our terms of use and privacy policy.

You can now claim free CME credits for this literature searchClaim now

Get seemless 1-tap access through your institution/university

For the best experience, use the Read mobile app